Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03043872
Title Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca

lung small cell carcinoma


Carboplatin + Cisplatin + Durvalumab + Etoposide + Tremelimumab

Carboplatin + Cisplatin + Durvalumab + Etoposide

Carboplatin + Cisplatin + Etoposide

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.